Serotonin dysregulation in Fragile X Syndrome: Implications for treatment

Alicia C. Hanson, Randi J Hagerman

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Fragile X Syndrome (FXS) is a trinucleotide repeat disorder that results in the silencing of the Fragile X Mental Retardation 1 gene (FMR1), leading to a lack of the FMR1 protein (FMRP). FMRP is an mRNA-binding protein that regulates the translation of hundreds of mRNAs important for synaptic plasticity. Several of these pathways have been identified and have guided the development of targeted treatments for FXS. Here we present evidence that serotonin is dysregulated in FXS and treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline may be beneficial for individuals with FXS, particularly in early childhood.

Original languageEnglish (US)
Pages (from-to)110-117
Number of pages8
JournalIntractable and Rare Diseases Research
Issue number4
StatePublished - 2014


  • fragile X mental retardation protein
  • Fragile X Syndrome
  • selective serotonin reuptake inhibitors
  • sertraline

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Serotonin dysregulation in Fragile X Syndrome: Implications for treatment'. Together they form a unique fingerprint.

Cite this